# Alzheimer's Breakthroughs: Trials, Treatments, and Hope Newsy: Alzheimer’s News Weekly Published: 2025-11-24T14:30:00.534Z Source: https://newsyai.com/edition/de8c81a3-e4eb-40ad-80cc-b61fc335b788 Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md --- # The Alzheimer’s Treatment Briefing Coverage period: November 18–24, 2025 (U.S.) Note up front: This week delivered one decisive late‑stage drug result and several practice‑relevant updates that affect how (and whom) we treat, plus a basic‑science finding that points to new ways to stop the disease earlier. ## Top stories (ranked) 1) Novo Nordisk’s semaglutide fails in two Phase 3 Alzheimer’s trials - What’s new (Nov 24) - The oral form of semaglutide did not slow decline versus placebo in EVOKE and EVOKE+ (about 3,800 people with early Alzheimer’s over two years). Full data are slated for presentation at CTAD on Dec 3. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-says-alzheimers-drug-trial-fails-meet-main-goal-2025-11-24/?utm_source=openai)) - Why this matters - Hopes that the diabetes/weight‑loss drug class (GLP‑1s) could double as an Alzheimer’s treatment took a major hit. For now, care remains centered on anti‑amyloid antibodies and supportive measures, while prevention‑oriented GLP‑1 research may continue separately. Expect therapy focus (and investment) to consolidate around proven amyloid and tau targets. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-says-alzheimers-drug-trial-fails-meet-main-goal-2025-11-24/?utm_source=openai)) 2) Real‑world lecanemab study (prospective, single center) reports early safety and imaging outcomes - What’s new (published Nov 17) - In 76 patients with early Alzheimer’s treated in routine care (Eastern China), infusion reactions occurred in 18% (mostly after the first dose), ARIA was seen in 11 patients and was asymptomatic in all; 12‑month amyloid PET showed significant plaque reduction among those imaged. ([alzres.biomedcentral.com](https://alzres.biomedcentral.com/articles/10.1186/s13195-025-01886-5)) - Why this matters - While small and single‑center, this prospective report supports what clinics are seeing: manageable safety with careful MRI monitoring and measurable amyloid lowering outside trials. It helps set expectations for patients and programs scaling treatment. ([alzres.biomedcentral.com](https://alzres.biomedcentral.com/articles/10.1186/s13195-025-01886-5)) 3) Lecanemab CTAD preview: more on long‑term benefit, clinic time saved, and starting with injections - What’s new (Nov 18) - Eisai will present: analyses on continued therapy and projected time savings over 10 years; safety/benefit of starting lecanemab with a subcutaneous regimen; effects on soluble amyloid protofibrils; and new real‑world data (including ALZ‑NET). ([prnewswire.com](https://www.prnewswire.com/news-releases/new-data-on-lecanemab-to-be-presented-at-ctad-conference-302619387.html?utm_source=openai)) - Why this matters - If initiating therapy by injection proves practical and safe, it could cut infusion‑center bottlenecks and speed access—especially important as more patients are identified by blood tests. Maintenance at‑home injections are already FDA‑cleared; the new angle is whether starting by injection can work too. ([prnewswire.com](https://www.prnewswire.com/news-releases/new-data-on-lecanemab-to-be-presented-at-ctad-conference-302619387.html?utm_source=openai)) 4) Basic‑science advance: dissolving “starter” tau clusters may block later toxic tangles - What’s new (coverage Nov 17–19; paper Oct 1) - Researchers identified tiny, soft clusters of tau that form before tangles. In lab systems, changing salt conditions disrupted these early clusters and largely prevented tangle formation—suggesting a new prevention‑first target. ([eurekalert.org](https://www.eurekalert.org/news-releases/1105643?utm_source=openai)) - Why this matters - Today’s drugs attack established pathology. A therapy that prevents tau from aggregating in the first place—by targeting reversible early clusters—could shift treatment earlier and potentially be combined with anti‑amyloid approaches. It’s preclinical, but it gives drug makers a clear, testable mechanism. ([eurekalert.org](https://www.eurekalert.org/news-releases/1105643?utm_source=openai)) 5) Smarter monitoring: new method adds “error bars” to individual biomarker forecasts - What’s new (Nov 17 preprint) - A conformal‑prediction framework creates uncertainty‑calibrated bands around a person’s future brain and fluid biomarker trajectories, improving identification of those at high risk of faster progression. ([arxiv.org](https://arxiv.org/abs/2511.13911?utm_source=openai)) - Why this matters - In clinic and trials, we don’t just need a prediction—we need to know how confident to be. Reliable “margins of error” can reduce false alarms, sharpen selection for disease‑slowing therapy, and time follow‑up scans more efficiently. ([arxiv.org](https://arxiv.org/abs/2511.13911?utm_source=openai)) ## What this means for care right now - Anti‑amyloid antibodies remain the evidence‑based disease‑slowing option for early Alzheimer’s. Practicalities (MRI monitoring, infusion vs. injection pathways) drive real‑world success. ([alzres.biomedcentral.com](https://alzres.biomedcentral.com/articles/10.1186/s13195-025-01886-5)) - Expect detailed GLP‑1 results at CTAD, but don’t plan around them for symptomatic treatment given today’s miss. Prevention studies may still explore metabolic pathways. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-says-alzheimers-drug-trial-fails-meet-main-goal-2025-11-24/?utm_source=openai)) - Watch for CTAD data on starting lecanemab with injections; if positive, this could simplify initiation and widen access in 2026. ([prnewswire.com](https://www.prnewswire.com/news-releases/new-data-on-lecanemab-to-be-presented-at-ctad-conference-302619387.html?utm_source=openai)) ## Quick takeaways for patients and caregivers - If you’re evaluating lecanemab: ask your center about safety monitoring, timelines to maintenance dosing, and whether an injection pathway is offered after the initial period. ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/eisai-and-biogen-announce-us-availability-leqembir-iqliktm?utm_source=openai)) - Don’t be discouraged by the GLP‑1 news. Proven risk‑reduction steps—blood‑pressure control, hearing/vision care, physical and social activity—still matter and can complement disease‑slowing drugs. (General guidance reinforced by ongoing literature.) - Stay tuned for CTAD (Dec 1–4) for practical updates that may change workflows more than headlines. ## In case you missed it recently (access and logistics) - At‑home maintenance injections for lecanemab (IQLIK autoinjector) are available in the U.S. after 18 months of IV therapy; programs and nurse‑training support are rolling out site by site. ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/eisai-and-biogen-announce-us-availability-leqembir-iqliktm?utm_source=openai)) --- If you want, I can deliver a rapid, plain‑English digest from CTAD (Dec 1–4) focused strictly on what changes for patient care.